What is he best known for?
The fields of study he is best known for:
- Antibody
- Gene
- Immune system
His primary areas of investigation include Antibody, Antigen, Cytotoxic T cell, Immunology and CD3.
CD19 is the focus of his Antibody research.
His work carried out in the field of Antigen brings together such families of science as Molecular biology and Pathology.
His research ties Immunotherapy and Cytotoxic T cell together.
Within one scientific family, Peter Kufer focuses on topics pertaining to Cytotoxicity under CD3, and may sometimes address concerns connected to Chinese hamster ovary cell.
His studies in T cell integrate themes in fields like Blinatumomab and CD8.
His most cited work include:
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody (895 citations)
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival (696 citations)
- A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity (413 citations)
What are the main themes of his work throughout his whole career to date?
Peter Kufer mainly investigates Antibody, Antigen, T cell, Immunology and Molecular biology.
His Antibody research is multidisciplinary, incorporating perspectives in Cancer research and CD3.
His Cancer research study combines topics from a wide range of disciplines, such as Cancer cell, Epithelial cell adhesion molecule, Prostate cancer and Immunotherapy.
His research on Antigen also deals with topics like
- Cytotoxicity which connect with Chinese hamster ovary cell,
- Cancer that connect with fields like Pathology.
His T cell study incorporates themes from Cytotoxic T cell, CD8 and Cell biology.
In most of his Molecular biology studies, his work intersects topics such as In vitro.
He most often published in these fields:
- Antibody (55.44%)
- Antigen (41.45%)
- T cell (35.23%)
What were the highlights of his more recent work (between 2015-2021)?
- Antibody (55.44%)
- T cell (35.23%)
- Cancer research (25.39%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Antibody, T cell, Cancer research, CD3 and Blinatumomab.
His biological study spans a wide range of topics, including Cell biology, Cell and In vitro, Cytotoxicity.
The T cell study combines topics in areas such as Ex vivo, Cytotoxic T cell, Molecular biology and Antigen.
His Cytotoxic T cell research integrates issues from Single-chain variable fragment and Virology.
His Cancer research research includes themes of Immune checkpoint, Immunotherapy, Cancer cell and Castration resistant, Prostate cancer.
His CD3 study incorporates themes from Binding domain, Bispecific antibody and CD33.
Between 2015 and 2021, his most popular works were:
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study (209 citations)
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. (145 citations)
- Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia (48 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Antibody
- Immune system
His main research concerns Blinatumomab, T cell, Internal medicine, Cancer research and Immunology.
His Blinatumomab research is included under the broader classification of CD19.
His research investigates the link between T cell and topics such as Ex vivo that cross with problems in Immunodeficiency, Virology, Viral load, Cytotoxic T cell and Single-chain variable fragment.
The various areas that Peter Kufer examines in his Cancer research study include CD3, Castration resistant, Prostate cancer, Poor prognosis and Antibody.
His research integrates issues of Lineage, Phases of clinical research and Relapse free survival in his study of Immunology.
Peter Kufer has researched Immune system in several fields, including Tumor necrosis factor alpha, Interferon, Antigen and Cytotoxicity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
